Notably, CD4+ CTL able to kill specific tumor cells have been described in several cancer types, including non-small-cell lung carcinoma (NSCLC), cutaneous T-cell lymphoma, and melanoma (35–39); for review, see Ref. This evidence concerns the gene CD4 and cancer.